Shire (SHPGF) Short-Term Debt : $4,239 Mil (As of Sep. 2018)

View and export this data going back to . Start your Free Trial

What is Shire Short-Term Debt?

Shire's Short-Term Debt for the quarter that ended in Sep. 2018 was $4,239 Mil.

Shire's quarterly Short-Term Debt increased from Mar. 2018 ($0 Mil) to Jun. 2018 ($1,185 Mil) and increased from Jun. 2018 ($1,185 Mil) to Sep. 2018 ($4,239 Mil).

Shire's annual Short-Term Debt increased from Dec. 2015 ($1,513 Mil) to Dec. 2016 ($3,062 Mil) but then declined from Dec. 2016 ($3,062 Mil) to Dec. 2017 ($2,781 Mil).

Shire Short-Term Debt Historical Data

The historical data trend for Shire's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shire Short-Term Debt Chart

Shire Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Short-Term Debt

Get a 7-Day Free Trial

850.00

1,512.70

3,061.60

2,781.20

Shire Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Short-Term Debt	Get a 7-Day Free Trial															2,622.20	2,781.20	-	1,184.60	4,239.20

Shire Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Shire Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Shire's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Shire (SHPGF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (OTCPK:SHPGF) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.shire.com

Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.